This study is for adults with Acute Myeloid Leukemia (AML), a type of blood cancer, who cannot or choose not to have strong chemotherapy. The goal is to see if a combination of three drugs: BP1001, venetoclax, and decitabine works better than just two: venetoclax and decitabine. BP1001 is a special drug that may stop cancer cells from growing by blocking a protein called Grb2.
Participants will be grouped based on their type of AML: those who haven't been treated yet, those whose cancer has returned or didn't respond to treatment, and those who can't take venetoclax. The study will be open-label, meaning everyone knows what treatment they are getting. Each group will start with 19 people and may include more if needed.
Key Points:- This study involves multiple visits and is open to adults 18 and older.
- Participants should not have other active cancers or serious health issues.
- Both men and women must use birth control during and after the study.
How understandable was the trial content above?
Hard to understand
Easy to understand